UK-based pharmaceutical company GSK has reported positive outcomes from two Phase III trials of depemokimab for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.
The ANCHOR-1 and ANCHOR-2 trials showed that twice-yearly administration of the antibody led to ‘clinically meaningful’ and statistically significant ‘improvements’ in nasal polyp size and obstruction compared to placebo.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
ANCHOR-1 enrolled 271 subjects while 257 subjects took part in the ANCHOR-2 study.
A pooled analysis of both trials showed notable reductions from baseline in nasal polyp score (NPS) at 52 weeks and mean nasal obstruction scores (VRS) for over weeks 49-52.
GSK said that treatment benefits had been noted by the first evaluation and sustained to week 52.
Secondary endpoint analyses from both trials found ‘significant improvements’ in patients who were given the antibody, such as loss of smell VRS score and rhinorrhoea VRS score.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGSK respiratory, immunology/inflammation R&D global head and SVP Kaivan Khavandi said: “Today’s data build on the body of evidence supporting depemokimab as an ultra-long-acting treatment and demonstrate significant reductions in nasal polyps with a twice-yearly dosing regimen.
“With nearly 40% of patients needing repeat surgeries and many requiring long-term systemic corticosteroids, there is a clear medical need for alternative treatment options to provide sustained symptom improvement and help alleviate the debilitating burden of this disease.”
CRSwNP is a chronic condition that occurs due to inflammation of the nasal lining and can cause nasal polyps to form.
Data from the ANCHOR and SWIFT trials are being used to support regulatory filings for depemokimab in various nations for the treatment of asthma with type 2 inflammation and CRSwNP.
The antibody is currently not approved for these indications in any country.
In December 2024, GSK reported that the Phase III FIRST-ENGOT-OV44 trial of Zejula and Jemperli met its primary endpoint of progression-free survival in treating first-line advanced ovarian cancer.
